| Identification | Back Directory | [Name]
Sakakin | [CAS]
21082-33-7 | [Synonyms]
Sakakin
Sakakin (8CI)
Orcinol glucoside
Orcinol β-D-glucoside
1-O-β-D-Glucosylorcinol
Orcinol beta-D-glucoside
1-O-beta-D-Glucosylorcinol
Orcinol β-D-glucopyranoside
Orcinol beta-D-glucopyranoside
Orcinol-3-O-β-D-glycopyranoside
Orcinol-3-O-beta-D-glycopyranoside
β-D-Glucopyranoside, 3-hydroxy-5-methylphenyl
3-Hydroxy-5-methylphenyl beta-D-Glucopyranoside
beta-D-Glucopyranoside 3-hydroxy-5-methylphenyl
1-α-O-D-glueopyranosyloxy-3-hydroxy-5-Methylbenzene
(2R,3S,4S,5R)-2-(hydroxymethyl)-6-(3-hydroxy-5-methylphenoxy)oxane-3,4,5-triol
(3R,4S,5S,6R)-2-(3-Hydroxy-5-methylphenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol | [Molecular Formula]
C13H18O7 | [MDL Number]
MFCD23135284 | [MOL File]
21082-33-7.mol | [Molecular Weight]
286.278 |
| Chemical Properties | Back Directory | [Melting point ]
138 °C(Solv: methanol (67-56-1); ethanol (64-17-5)) | [Boiling point ]
570.6±50.0 °C(Predicted) | [density ]
1.497 | [storage temp. ]
?20°C | [solubility ]
Soluble in ethan | [form ]
powder to crystal | [pka]
9.55±0.10(Predicted) | [color ]
White to Light gray to Light yellow | [Major Application]
metabolomics
vitamins, nutraceuticals, and natural products | [InChI]
InChI=1/C13H18O7/c1-6-2-7(15)4-8(3-6)19-13-12(18)11(17)10(16)9(5-14)20-13/h2-4,9-18H,5H2,1H3/t9-,10-,11+,12-,13?/s3 | [InChIKey]
YTXIGTCAQNODGD-GFLOTHHYNA-N | [SMILES]
C1(OC2=CC(C)=CC(O)=C2)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O |&1:11,14,16,18,r| |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
36 | [Safety Statements ]
26 | [WGK Germany ]
3 | [HS Code ]
2938.90.0000 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral
Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| Hazard Information | Back Directory | [Chemical Properties]
Pale yellow crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Curculigo orchioides. | [Uses]
Orcinol Glucoside produces antidepressant effects blocking behavioural and neuronal deficits. |
|
|